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When Miracle Cures Go Bad: Regulators’
Responses to Unproven Direct-toConsumer Stem Cell Therapies
Sydney Hope*
I. INTRODUCTION
Dorothy O’Connell was a normal and active eighty-nine year old.1
However, she suffered from arthritis and was almost always in pain.2 So,
when her daughter heard about the potential of stem cell treatments, she was
hopeful they would eliminate her mother’s pain.3 After Dorothy received
these treatments, her condition got worse, not better.4 Instead of finding herself miraculously cured by the treatments, Dorothy found herself on the
verge of a heart attack and with failing kidneys.5 After spending almost two
months in the hospital and rehab, Dorothy was able to learn to walk again but
still has continuing damage from the stem cell injections.6 Dorothy’s story is
just one of many that involve unproven stem cell treatments gone wrong.7
These patients are often promised a miracle cure to their condition.8
However, unbeknownst to the patients, these treatments are unproven and the
negative impacts are unknown.9 The clinics that advertise treatments do so
without testing them in well-controlled trials.10 Due to the growing number
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of patients harmed by such deceptive advertising of unproven treatments,
regulators have increased their regulation of these clinics.11 Even with this
increased enforcement, clinics continue to circumvent such regulations until
after patients have already been harmed.12 This Comment will discuss the
direct-to-consumer stem cell industry, current U.S. Food and Drug Administration (FDA) regulation, and alternative approaches to effectively regulate
these clinics.
A. Stem Cell Treatments
Regenerative medicine, particularly stem cell therapy, has been developing for decades.13 Stem cells can divide and transform into other types of
cells in order to replace or replenish tissues.14 Because of these potential
healing benefits, the field has attracted serious investment and attention.15
However, while there are significant benefits to these therapies, regulation of
them is not simple.16 Stakeholders in the field have advocated for less rigorous regulations to allow for the innovation of lifesaving therapies.17 Others
have argued that more stringent regulations are necessary to ensure patient
safety.18
Regulators must therefore find a balance between promoting innovation
in this advancing industry and ensuring patients’ safety and efficacy of the
treatments.19 Within the current framework of regulations, therapies that are
not approved by the FDA are still marketed to consumers.20 This direct-toconsumer industry has become a significant concern for regulators and stakeholders in the industry.21 Given the significant areas of laws, regulations, and
11. Statement from FDA Commissioner Scott Gottlieb, M.D. on the FDA’s New
Policy Steps and Enforcement Efforts to Ensure Proper Oversight of Stem Cell
Therapies and Regenerative Medicine, U.S. FOOD & DRUG ADMIN. (Aug. 28,
2017), https://www.fda.gov/news-events/press-announcements/statement-fdacommissioner-scott-gottlieb-md-fdas-new-policy-steps-and-enforcement-efforts-ensure [hereinafter Statement of FDA Commissioner].
12. PEW CHARITABLE TRS., FDA’S FRAMEWORK FOR REGULATING REGENERATIVE
MEDICINE WILL IMPROVE OVERSIGHT 6 (2019) (describing how stem clinics
offering unproven treatments argue they are not subject to FDA regulation).
13.

Id. at 2.

14.

Id. at 4.

15.

Id. at 1.

16. Sarah Duranske, Reforming Regenerative Medicine Regulation, 34 GA. ST.
U.L. REV. 631, 633 (2018).
17.

Id.

18.

Id.

19.

Id.

20. PEW CHARITABLE TRS., supra note 12, at 6.
21. Id. at 1.
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treatment opportunities in the stem cell industry, this Comment will focus on
the area of unregulated stem cell treatments that are marketed directly to
consumers.
Part II of this Comment gives an introduction to the direct-to-consumer
industry for stem cell treatments nationally and on a state level. Part III discusses the current state of regulation including statutes, rules promulgated by
the FDA, guidance drafted by the FDA discussing key terms and exceptions
to the regulations, and the recent case United States v. US Stem Cell Clinic,
LLC. Parts IV and V describe the impact of unclear regulations and unregulated treatments. In these parts, the author argues that regulations need further clarification from the FDA regarding therapies which fall under
regulation and conclude the FDA needs to interact with other federal agencies and state actors to increase regulation in this area.
B. Bad Batch Podcast
The stem cell therapy industry, particularly the use of unregulated treatments (discussed in Part II below) is the focus of the recent investigative
podcast Bad Batch.22 Bad Batch focuses on the company Liveyon, which
processes and distributes stem cells derived from umbilical cord blood.23 The
podcast also highlights the stories of Texas patients who had bad outcomes
after being injected with stem cells distributed by Liveyon.24 Several patients
in Texas, including Dorothy O’Connell, received injections of stem cells
from a chiropractor in Houston.25 These stem cell treatments were not FDA
approved and Liveyon has since been reprimanded by the FDA.26 Through
interviews with the CEO of Liveyon and patients who received stem cell
treatments, the podcast sheds light on the growing industry of stem cell treatments and its real world implications.27 The podcast is continuously referenced throughout this Comment in order to explore the topic of unregulated
stem cell treatments.

22. Will Maddox, Laura Beil’s New Podcast Bad Batch Sheds Light on the World
of Unregulated Stem Cell Treatment, D MAG. (Nov. 5, 2019), https://
www.dmagazine.com/arts-entertainment/2019/11/laura-beils-new-podcast-badbatch-sheds-light-on-the-world-of-unregulated-stem-cell-treatment/.
23. Beil, supra note 1; Wan & McGinley, supra note 8.
24. Beil, supra note 1.
25.

Id.

26. Laurie McGinley, California Stem Cell Company Halts Sales After FDA Warning, WASH. POST (Dec. 13, 2019), https://www.washingtonpost.com/health/
2019/12/13/california-stem-cell-company-halts-sales-after-fda-warning/.
27. Maddox, supra note 22.
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II. DIRECT-TO-CONSUMER STEM CELL INDUSTRY
A. The Industry
Although there are only a few stem cell therapies currently approved for
clinical application, this has not stopped private clinics from advertising
treatments that are not FDA approved for a variety of medical conditions.28
This industry is a “vast medical experiment, uncontrolled, unsupervised, unreported, and conducted on a for-profit basis.”29 It is comprised of businesses
that are able to develop plans to avoid premarket testing for efficacy and
patient safety.30 As the field of regenerative medicine evolved, it became
unclear who was responsible for regulating these businesses, which opened
the door to businesses marketing unsafe and ineffective products.31 Researchers found that about half of the stem cell clinics in Texas, California, and
Florida do not seem to have doctors with the necessary “formal training
matching the conditions they treat.”32
Many of these companies market directly to consumers through online
resources.33 In marketing to consumers, the websites sometimes include hype
language that exaggerates the potential benefits of the therapy.34 Clinic websites advertise therapies derived from sources such as bone marrow, blood,
and umbilical cords.35 These therapies are advertised as treatments for common bone pain, joint pain, muscle injuries, and other illnesses (such as
autoimmune disorders, degenerative conditions, and other chronic conditions).36 These various therapies are targeted at vulnerable populations who
are looking to this treatment as their last hope.37 Many times, these claims
about the treatments are not supported by reliable evidence.38 Despite the fact
28. Blake Murdoch et al., Exploiting Science? A Systematic Analysis of Complementary and Alternative Medicine Clinic Websites’ Marketing of Stem Cells
Therapies, 8 BMJ OPEN 1, 1 (2018), https://bmjopen.bmj.com/content/
bmjopen/8/2/e019414.full.pdf.
29. Douglas Sipp, Direct-to-Consumer Stem Cell Marketing and Regulatory
Processes, 2 STEM CELLS TRANSLATIONAL MED. 638, 638 (2013), https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC3754464/pdf/sct638.pdf.
30. Id.
31. PEW CHARITABLE TRS., supra note 12, at 1.
32. Sangita Menon, Texas Ranks Third for Number of Stem Cell Clinics. But That
May Not Be a Good Thing, KUT (July 8, 2019), https://www.kut.org/post/
texas-ranks-third-number-stem-cell-clinics-may-not-be-good-thing.
33. Murdoch et al., supra note 28, at 1–2.
34. Id. at 5.
35. Id. at 1.
36. Id. at 4.
37. PEW CHARITABLE TRS., supra note 12, at 6.
38. Murdoch et al., supra note 28, at 1.
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that these therapies are not FDA approved, research has shown that clinics
often do not disclose to patients the experimental or unproven nature of the
treatments.39 Further, clinics do not regularly warn patients about the limited
evidence of efficacy or inefficacy.40 Also, clinics often do not disclose information about the risks specific to the therapy.41 Even if a business seeks to
indemnify themselves by disclosing the experimental nature and risks of the
treatment, the waivers benefit the providers rather than help the patient.42
In addition to these online advertisements, businesses also participate in
“regulatory shopping” to provide unregulated treatments.43 Through this process, businesses set up clinics in neighboring areas with less strict regulations.44 This practice shifts the liability to the patients who come in for
treatment.45 Patients assume the risk of undergoing procedures potentially
outside the standard of care and lose the legal protections available from
stricter regulations.46
B. Unregulated Therapies in Texas
While the use of unregulated stem cell treatments are a national issue,
Austin, Texas has become a hot spot for direct-to-consumer stem cell clinics.47 In 2017, out of the 716 clinics in the United States that advertised stem
cell treatments, 100 of them were in Texas.48 The large number of clinics in
Texas can partly be explained by the business-friendly regulations in the
state.49 Texas has more lenient regulations at the state level, which allow
investigational treatments that are not FDA approved to be administered in
certain circumstances.50 Some argue these laws opened the door for the expansion of clinics to further practice unproven treatments.51
A law passed in Texas in 2017 allows investigational stem cell treatments for patients with severe chronic diseases or terminal illnesses who sign
39. Id. at 6.
40. Id.
41. Id.
42. Sipp, supra note 29, at 639.
43. Id. at 638–39.
44. Id. at 639.
45. Id.
46. Id.
47. Menon, supra note 32.
48. Id.
49. Maddox, supra note 22.
50. Menon, supra note 32.
51. Id.
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a written informed consent.52 The treatment must be administered directly by
a physician who is certified by an institutional review board.53 The treatment
must also be overseen by an institutional review board that is affiliated with a
medical school, is affiliated with a hospital, is accredited by the Association
of the Accreditation of Human Research Programs, is registered by the U.S.
Department of Health and Human Services, or is accredited by a national
accreditation organization acceptable to the Texas Medical Board.54 The government may not interfere with a patient’s access to this treatment unless the
product is considered adulterated or misbranded, which cannot be based
solely on the fact that the FDA has not approved the product.55
Proponents of the law claim that the law opens the door to medical
advancement.56 The law gives those who are researching stem cells and regenerative medicine more data—both positive and negative.57 This research
allows for the vetting of the therapies to make sure that innovation is happening safely.58 The law has been criticized, however, because it opens the door
to potentially more unproven and controversial treatments that risk patient
safety.59
III. FDA REGULATORY FRAMEWORK
The FDA has released several statements and warnings about the use of
unapproved stem cell treatments.60 In a statement on August 28, 2017, the
former FDA commissioner, Scott Gottlieb, stated the importance of regulating this area where “a select few, often motivated by greed without regard to
responsible patient care, are able to promote unproven, clearly illegal, and
often expensive treatments that offer little hope, and, even worse, may pose
significant risks to the health and safety of vulnerable patients.”61 The FDA
has stated it will increase its oversight and enforcement to protect patients
52. TEX. HEALTH & SAFETY CODE ANN. §§ 1003.053–054 (West 2017).
53. Id. § 1003.055 (Westlaw).
54. Id.
55. Id. § 1003.058 (Westlaw).
56. Britni R. McAshan, New Law Opens Doors for Regenerative Medicine in
Texas, TEX. MED. CTR. (Oct. 9, 2017), https://www.tmc.edu/news/2017/10/
new-law-opens-doors-regenerative-medicine-texas/.
57. Id.
58. Id.
59. Menon, supra note 32.
60. FDA Warns About Stem Cell Therapies, U.S. FOOD & DRUG ADMIN., https://
www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies (last updated Aug. 3, 2019); Statement of FDA Commissioner, supra note
11.
61. Statement of FDA Commissioner, supra note 11.
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from dishonest stem cell treatments.62 However, even with this increased
oversight, the FDA still wants to encourage medical innovation so stem cell
products can be used in proper ways.63 In its warning on stem cell therapies,
the FDA says it will take administrative, judicial, or criminal action depending on the violation.64
Part of the FDA review for approval, described in detail below, includes
showing the agency how each product is manufactured so it can ensure appropriate procedures to “assure the product’s safety, purity, and strength.”65
Despite clinics falsely advertising that FDA approval of their treatment is
unnecessary, the FDA has clearly taken the stance that these treatments do
fall under their regulations.66 If a clinical trial is not completed under an
Investigational New Drug Application, then the FDA has not reviewed the
therapy to ensure safety and it is not FDA approved.67
A. Statutes
There are three core statutes that give the FDA the authority to regulate
stem cell treatments: the Federal Food, Drug, and Cosmetic Act (FD&C
Act), Public Health Services Act (PHSA), and the 21st Century Cures Act.68
The FD&C Act gives the FDA the authority to regulate drugs and devices
that are “intended for the use in the diagnosis, cure, mitigation, treatment, or
prevention of disease . . . or to affect the structure or any function of the
body.”69 Under this Act, any new drug must be approved before it can be
introduced into interstate commerce.70 To achieve approval, an application
must be filed which includes reports of investigations showing whether or
not the drug is effective; a list of articles used as components in the drug; a
description of methods, facilities, and controls used in manufacturing,
processing, and packaging of the drug; samples of the drug and articles used
as components; and any other assessments required under Section 355(c).71
So, manufacturers must “demonstrate that the product is safe and effective on
the basis of adequate and well-controlled clinical trials.”72
62. FDA Warns About Stem Cell Therapies, supra note 69.
63. Id.
64. Id.
65. Id.
66. Id.
67. Id.
68. PEW CHARITABLE TRS., supra note 12, at 7–8.
69. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 321(g)(1), (h)(2)–(3)
(2018).
70. Id. § 355(a).
71. Id. § 355(b)(1).
72. PEW CHARITABLE TRS., supra note 12, at 7.
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Sections 351 and 361 of the PHSA also apply to stem cell treatments.
Section 351 regulates the interstate commerce of biologic products.73 A biologic product is a product that is “applicable to the prevention, treatment or
cure of a disease or condition of human beings.”74 The biologic products
under this Act are subject to the same regulations under the FD&C Act, except that they are approved under a biologics license under 42 U.S.C.
§ 262(a).75 Section 361 authorizes regulations “necessary to prevent the introduction, transmission, or spread of communicable diseases.”76 Human cell
products may be subject to Section 351 or 361 regulations depending on
what tier of regulation they fall under, discussed more below.77
Section 3303 of the 21st Century Cures Act created an accelerated review of Regenerative Medical Advanced Therapies (RMATs).78 For a drug
to be considered for RMAT designation, it must meet three criteria.79 The
first requirement is that it must be a regenerative medicine therapy as defined
in the Act.80 Regenerative medicine therapy includes “cell therapy, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies and products” that are not regulated
solely under PHSA § 361 and 21 C.F.R. § 1271.81 There will be further discussion of which drugs fall under these regulations below. The second requirement for RMAT designation is that the drug is “intended to treat,
modify, reverse, or cure a serious or life threatening disease or condition.”82
Life-threatening diseases or conditions are at a stage where there is a reasonable likelihood that death will occur within months or where premature death
is likely.83 A serious disease or condition is “a disease or condition associated
with morbidity that has substantial impact on day-to-day functioning.”84 The
final requirement for RMAT designation is that “preliminary clinical evidence indicates that the drug has the potential to address unmet medical
needs for such a disease or condition.”85 For a medical need to be unmet, the
treatment or diagnosis cannot be addressed adequately by available therapy
73. Public Health Services Act, 42 U.S.C. § 262(a)(1) (2018).
74. Id. § 262(i).
75. Id. § 262(j).
76. Id. § 264(a).
77. PEW CHARITABLE TRS., supra note 12, at 7.
78. 21 U.S.C. § 356(g)(1) (2018).
79. Id. § 356(g)(2).
80. Id. § 356(g)(2)(A).
81. Id. § 356(g)(8).
82. Id. § 356(g)(2)(B).
83. 21 C.F.R. § 312.300(b) (2019).
84. Id.
85. 21 U.S.C. § 356(g)(2)(C).
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and includes “an immediate need for a defined population . . . or a longerterm need for society.”86
B. Risk-Based Regulatory Tiers Under 21 C.F.R. § 1271
Title 21 of the Code of Federal Regulations creates a tiered risk-based
approach for the regulation of human cells, tissue, and cellular and tissuebased products (HCT/Ps).87 HCT/Ps are defined as “articles containing or
consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient.”88 In creating this
risk-based approach, the FDA was concerned with several public health and
regulatory concerns including the prevention of communicable diseases;
preventing contamination of products and preserving its integrity and function; and ensuring safety and effectiveness of the product.89 Under the lowest
tier, these regulations exempt certain HCT/Ps from the premarket and review
requirements under the FD&C Act and PHSA.90 HCT/Ps that fall under the
middle tier regulation are exempt from the premarket conditions from the
FD&C Act and Section 351 of the PHSA.91 Thus, they are solely regulated
under PHSA § 361 and 21 C.F.R. § 1271.92 The highest tier of regulation
treats the HCT/P as a drug, device, or biologic product under the FD&C Act
and Section 351 of the PHSA and are subject to premarket approval and
review under these statutes.93
1. Lowest Tier Regulations
21 C.F.R. § 1271.3(d) by its text excludes several articles from the definition of HCT/Ps.94 This includes human organs for transplantation, blood
vessels recovered with an organ intended for use in organ transplantation,
secreted or extracted human products, minimally manipulated bone marrow
for homologous use and not combined with another article, ancillary products
86. U.S. FOOD & DRUG ADMIN., EXPEDITED PROGRAMS FOR REGENERATIVE
MEDICINE THERAPIES FOR SERIOUS CONDITIONS 3 (2019), https://www.fda.gov/
media/120267/download.
87. 21 C.F.R. § 1271.1(b) (2019).
88. Id. § 1271.3(d).
89. U.S. FOOD & DRUG ADMIN., REGULATORY CONSIDERATIONS FOR HUMAN
CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS: MINIMAL MANIPULATION AND HOMOLOGOUS USE 3 (2020), https://www.fda.gov/media/
109176/download [hereinafter MINIMAL MANIPULATION AND HOMOLOGOUS
USE].
90. Id. at 5.
91. Id.
92. Id.
93. Id. at 3–4.
94. 21 C.F.R. § 1271.3(d) (2019).
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used in the manufacture of the HCT/Ps, and in vitro diagnostic products.95 By
their exclusion under the definition of HCT/Ps, these products are not subject
to the 21 C.F.R. § 1271 regulations.96
Other products that do fall under the HCT/P definition may be exempt
from the requirements under the list of exceptions in 21 C.F.R. § 1271.15.97
The same surgical procedure exception has received guidance and explanations over the years.98 This exception applies to an “establishment that
removes HCT/Ps from an individual and implants such HCT/Ps into the same
individual during the same surgical procedure.”99 In its guidance on this exception, the FDA explained that for an HCT/P to remain “such HCT/P,” the
only processing steps allowed are rinsing, cleansing, sizing, and shaping.100
The policy behind this exception is because without processing, there are no
additional risks of contamination or communicable disease than in a typical
surgery.101
Further, the FDA explained that generally the same surgical procedure,
is a single operation performed at the same establishment.102 However, there
are some circumstances where the surgery may be completed over several
days so long as there were no other processing steps between the removal
and implantation.103 Additionally, if one establishment ships the HCT/P to
another establishment, that shipping creates a manufacturing step that makes
the exception inapplicable.104
Many clinics advertise adipose-derived stem cell treatments, which they
claim are not subject to FDA regulations because they fall under the same
surgical procedure exception.105 In these treatments, “cells are removed from
processed fat tissue and then returned to the body.”106 While these treatments
95. Id.
96. Id.
97. Id. § 1271.15.
98. U.S. FOOD & DRUG ADMIN., SAME SURGICAL PROCEDURE: EXCEPTION UNDER
21 CFR 1271.15(B): QUESTIONS AND ANSWERS REGARDING THE SCOPE OF THE
EXCEPTION 2–3 (2017), https://www.fda.gov/media/89920/download [hereinafter SAME SURGICAL PROCEDURE EXCEPTION].
99. 21 C.F.R. § 1271.15(b).
100. SAME SURGICAL PROCEDURE EXCEPTION, supra note 98, at 5.
101. Id. at 3.
102. Id. at 5.
103. Id. at 5–6.
104. See id. at 6.
105. Leigh G. Turner, Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA
Draft Guidance Documents, 90 MAYO CLINIC PROC. 567, 568 (2015).
106. Id.
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do not come within the language of the exception, clinics still attempt to use
it to circumvent regulations.107 The potential for this misuse of the exception
indicates the need for stronger regulations of such clinics.108 Such regulation
could include stronger enforcement of regulations by the FDA or, as discussed more in Part V below, the use of other forms of regulation, such as
deceptive marketing, to more directly target these businesses.
2. Middle Tier Regulations
The rules also create a middle tier of regulations that are regulated
solely under Section 361 of PHSA and regulations in 21 C.F.R.
§ 1271.10(a).109 For an HCT/P to fall under this regulatory tier, it must meet
four criteria.110 The first requirement is that the HCT/P be minimally manipulated.111 The FDA considers minimal manipulation based on the impact on
the original relevant characteristics as the HCT/P exists in the donor, not on
the intended use in the recipient.112 Minimally manipulated is defined in
terms of structural tissues and cells or nonstructural tissues.113 The FDA has
explained the difference between the two types in their guidance on the issue.114 Structural tissues cannot be processed in ways that “alter the original
relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement.”115 Examples of these characteristics include strength, flexibility, and covering, among others.116 Cells or
nonstructural tissues cannot be processed in a way that “alter[s] the relevant
biological characteristics of cells or tissues.”117 Biological characteristics include metabolic activity, differentiation, and activation state.118
The second criteria for a HCT/P to fall under this tier is that it is “intended for homologous use only, as reflected by the labeling, advertising, or
107. Id.
108. Id. at 570.
109. 21 C.F.R. § 1271.10(a).
110. Id.
111. Id.
112. MINIMAL MANIPULATION

AND

HOMOLOGOUS USE, supra note 89, at 7.

113. 21 C.F.R. § 1271.3(f).
114. See MINIMAL MANIPULATION AND HOMOLOGOUS USE, supra note 89, at 8–9,
14 (Structural tissues “physically support or serve as a barrier, or conduit, or
connect, cover or cushion,” such as bone and skin. Nonstructural tissue or cells
serve a “metabolic or other biochemical role in the body such as hematopoietic,
immune, and endocrine functions,” such as reproductive cells or tissues.).
115. 21 C.F.R. § 1271.3(f)(1) (2019).
116. MINIMAL MANIPULATION

AND

HOMOLOGOUS USE, supra note 89, at 10.

AND

HOMOLOGOUS USE, supra note 89, at 14.

117. 21 C.F.R. § 1271.3(f)(2).
118. MINIMAL MANIPULATION
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other indications of the manufacturer’s objective intent.”119 Homologous use
is the “repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with an HCT/P that performs the same basic function or
functions in the recipient as in the donor.”120 It is not necessary that the cell
or tissue perform all of the same functions, but any basic function it is intended to perform in the recipient needs to be a basic function performed in
the donor.121 Thus, if a manufacturer states an unproved treatment can be
used for a “myriad of diseases or conditions, the HCT/P is likely not intended
for homologous use only.”122
The third condition for an HCT/P to be regulated solely under Section
361 and 21 C.F.R. § 1271 regulations is that the HCT/P cannot be combined
with another article (other than “water, crystalloids, or a sterilizing, preserving, or storage agent” if they do not raise new safety concerns).123 The final
requirement concerns the systemic effect of the HCT/P.124 The HCT/P cannot
have a systemic effect and cannot depend on the “metabolic activity of living
cells for its primary function.”125 Alternatively, if the HCT/P does have a
systemic effect or depends on the metabolic activity of living cells for its
primary function it must also be for autologous use,126 for allogenic use in a
blood relative, or for reproductive use.127
Manufacturers who manufacture an HCT/P that meets these criteria
must comply with regulations contained in 21 C.F.R. § 1271.128 The establishment must register with the FDA and submit a list of each HCT/P manufactured to the FDA.129 Additionally, manufacturers must follow the testing
and screening procedures for donor eligibility laid out in 21 C.F.R.
§ 1271.45–.90.130 The manufacturers must also follow the Current Good Tissue Practice to prevent the “introduction, transmission, or spread of commu119. 21 C.F.R. § 1271.10(a)(2).
120. Id. § 1271.3(c).
121. MINIMAL MANIPULATION AND HOMOLOGOUS USE, supra note 89, at 17 (A basic function is what an HCT/P does or can do in its “native state . . . as it exists
in the donor.”).
122. Id. at 16.
123. 21 C.F.R. § 1271.10(a)(3).
124. Id. § 1271.10(a)(4).
125. Id. § 1271.10(a)(4)(i).
126. Id. § 1271.3(a) (“Autologous use means the implantation, transplantation, infusion, or transfer of human cells or tissue back into the individual from whom
the cells or tissue were recovered.”).
127. Id. § 1271.10(a)(4)(ii).
128. Id. § 1271.10(a).
129. 21 C.F.R. § 1271.10(b).
130. .Id. § 1271.45.
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nicable diseases” under 21 C.F.R. § 1271.145–.320.131 These regulations are
not as stringent as those imposed on manufacturers of products regulated
under the FD&C Act and Section 351 of the PHSA.132 Further, these HCT/Ps
are not subject to the premarket approval regulations that apply to the highest
tier products.133
History has given several examples of therapeutic interventions that,
while supported by expert opinion, proved to be ineffective or harmful in
clinical trials.134 Even patients who received autologous stem cells, which
raise fewer safety concerns, have had negative outcomes such as the development of tumors and permanent blindness.135 Despite the fact that clinics
claim their treatments fall into the lower tiers of regulation, it has been established they are subject to more stringent regulations.136 This signifies that
increased regulation of these treatments, through alternative approaches addressed in Part V below, could increase patient safety overall.137
3. Highest Tier Regulations
HCT/Ps that do not meet the exceptions under 21 C.F.R. § 1271.15 or
meet the conditions above are regulated as a drug, device, or biologic product
under the FD&C Act and Section 351 of the PHSA.138 Thus, they require
premarket approval.139 As such, manufacturers must submit a new drug application or biologics license application before the product can be introduced into interstate commerce.140 The clinical investigation regulations are
the same for both new drugs and biologics.141
There are generally three phases of clinical investigation on new
drugs.142 The first phase involves a small population of subjects and patients
131. .Id. § 1271.145.
132. Duranske, supra note 16, at 642.
133. PEW CHARITABLE TRS., supra note 12, at 11.
134. Marks et al., supra note 9, at 1008.
135. Id.
136. FDA Warns About Stem Cell Therapies, supra note 60.
137. Liz Richardson, Lawsuit Highlights State Role in Regulating Regenerative
Medicine, PEW CHARITABLE TRS. (May 13, 2019), https://www.pewtrusts.org/
en/research-and-analysis/articles/2019/05/13/lawsuit-highlights-state-role-inregulating-regenerative-medicine (discussing the need for a broad effort among
state and federal regulators in protecting consumers from deceptive marketing
by these clinics).
138. 21 C.F.R. § 1271.20 (2019).
139. Id.
140. 21 U.S.C. § 355(b)(1) (2018); 42 U.S.C. § 262(a) (2019).
141. 21 C.F.R. § 312.2(a) (2019).
142. Id. § 312.21.
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who are closely monitored.143 This phase is designed to determine the effects
on humans, to help design phase two studies, and glean early evidence on the
drug’s effectiveness.144 Phase two studies are usually well controlled and
closely monitored to evaluate the drug’s effectiveness in patients with a specific disease or condition.145 These studies also determine common shortterm side effects and risks.146 Phase three are larger uncontrolled trials with
more subjects to gain additional information about the drug’s effectiveness
and safety.147 This information helps determine the general benefit-risk relationship of the drug.148 In phases two and three, the FDA is not only evaluating the safety of the subjects, but it is also assessing the quality of the
investigations and the likelihood that the investigation will gather sufficient
data for marketing approval.149
In addition, these products are subject to current good manufacturing
requirements.150 These requirements include the areas of manufacturing, personnel, equipment, standard operating procedures, quality control procedures, change and document controls, packaging and labeling, and record
keeping.151 Given these stringent regulations, it is easy to see why manufacturers and clinics attempt to argue they are in the unregulated lowest tier.152
However, the court in United States v. US Stem Cell Clinic, LLC held that
stem cell treatments are subject to these regulations.153 Despite this, stakeholders in the industry still believe that there is significant ambiguity where
they fall in this regulatory framework.154

143. Id. § 312.21(a).
144. Id.
145. Id. § 312.21(b).
146. Id.
147. 21 C.F.R. § 312.21(c).
148. Id.
149. Id. § 312.22(a).
150. Duranske, supra note 16, at 644 (citing Facts About the Current Good Manufacturing Practices, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/
developmentapprovalprocess/manufacturing/ucm169105.htm (June 25, 2018)).
151. Id. (citing 21 C.F.R. §§ 211, 601, 820 (2017)).
152. See Menon, supra note 32 (discussing how clinics nationwide attempt to evade
regulations by interpreting these regulations in ways so that they do not apply
to the clinics).
153. United States v. US Stem Cell Clinic, 403 F. Supp. 3d 1279, 1295 (S.D Fla.
2019).
154. PEW CHARITABLE TRS., supra note 12, at 16.
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The product sold by Liveyon, the focus of Bad Batch, is an example of a
product that would be regulated under this tier.155 The company has been
linked to fifteen patients who were hospitalized after being injected with the
products.156 These patients were negatively impacted by treatments that fell
into this tier of regulation but were not tested properly.157 These severe negative effects show why understanding the risks of treatments through wellcontrolled trials is imperative to patient safety.158 It further proves that increased regulation through deceptive marketing enforcement by the U.S.
Federal Trade Commission (FTC) or increased oversight by state medical
boards could be necessary to further prevent bad outcomes.159
It should be mentioned that there are right-to-try laws that allow access
to investigational drugs for terminally ill patients on both a state and federal
level.160 However, these laws are beyond the scope of this article, which will
focus on the use of unproven treatments on patients who would not qualify
for these laws.
C. FTC Enforcement Actions
1. Injunctions
In addition to these statements, the FDA recently brought an action
against U.S. Stem Cell Clinic, LLC, a clinic which provided adipose tissue
based treatment.161 The clinic advertised that the therapy could treat “neurological, autoimmune, orthopedic, and degenerative diseases.162 In this case,
the FDA claimed the clinic violated regulations through their stem cell treatments.163 These violations included a failure to establish and follow appropri155. The FDA sent Liveyon a warning letter that advised the company that their
umbilical cord products were subject to this level of regulation. Warning Letter
Liveyon Labs Inc., U.S. FOOD & DRUG ADMIN. (Dec. 5, 2019), https://
www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/liveyon-labs-inc-588399-12052019.
156. Wan & McGinley, supra note 8.
157. Id.
158. Marks et al., supra note 9, at 1008–09 (“Without such [clinical] studies, we
will not be able [to] ascertain whether the clinical benefits of such therapies
outweigh any potential harms.”).
159. See supra note 137 and accompanying text.
160. Christine Coughlin et al., Regenerative Medicine and the Right to Try, 18
WAKE FOREST J. BUS. & INTELL. PROP. L. 590, 611 (2018); Right to Try, U.S.
FOOD & DRUG ADMIN., https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try (last updated Jan. 14, 2020).
161. United States v. US Stem Cell Clinic, 403 F. Supp. 3d 1279, 1282 (S.D. Fla.
2019).
162. Id. at 1283.
163. Id.
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ate procedures to prevent contamination of products which put patients at
risk for infections.164 U.S. Stem Cell argued the procedure did not fall under
the FDA’s authority because of the same surgical procedure exemption and
thus they did not have to comply with the FDA regulations.165
The judge found that the FDA acted within its powers and that there was
a “reasonable likelihood” that the clinic would continue to violate the law.166
Regarding the same surgical procedure exception, the court deferred to the
FDA’s narrow interpretation.167 Under this interpretation, the therapy did not
fall under the exception because of the processing involved.168 The court further found that the therapy was not homologous use and therefore the company was subject to the highest tier of regulation.169
The judge ordered a permanent injunction to prevent the company from
offering stem cell treatments until they came into compliance with the law.170
This case shows how clinics attempt to circumvent regulation under the current regulatory scheme.171 The FDA responded to this case by saying it reinforces its position that clinics that claim they do not fall under FDA
regulations are not correct.172 Following this case, they will continue “aggressive oversight” prioritizing addressing clinics, individuals, and products that
put patients the most at risk.173 However, this response by the FDA may not
be enough to stop clinics from marketing such treatments without complying
with regulations.174
2. Warning Letters
The FDA also utilizes warning letters as part of its enforcement strategy.175 For example, a warning letter was sent to Liveyon.176 The letter was
164. Id.
165. Id. at 1283–84.
166. Id. at 1300.
167. US Stem Cell Clinic, 403 F. Supp. 3d at 1296.
168. Id.
169. Id. at 1298.
170. Id. at 1300.
171. See supra note 152 and accompanying text.
172. Statement on Stem Cell Clinic Permanent Injunction and FDA’s Ongoing Efforts to Protect Patients from Risks of Unapproved Products, U.S. FOOD &
DRUG ADMIN. (June 25, 2019) https://www.fda.gov/news-events/press-announcements/statement-stem-cell-clinic-permanent-injunction-and-fdas-ongoing-efforts-protect-patients-risks [hereinafter Statement on Stem Cell Clinic
Permanent Injunction].
173. Id.
174. See supra note 137 and accompanying text.
175. McGinley, supra note 26.
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sent to Liveyon and its president and chief executive officers warning them
of processing and distributing unapproved products.177 The letter also warned
of good manufacturing practice requirements (deficient donor eligibility, inadequate aseptic practices to prevent contamination, and deficient environmental monitoring).178
Liveyon was processing and distributing products to be used by patients
unrelated to the donor, for nonhomologous use.179 So, they failed to meet the
criteria set forth in relevant FDA regulations and are regulated as both a drug
and biological product.180 Under the regulations, these products may only be
used in humans if there is an investigational new drug application and can
only be lawfully marketed if they have a biologic license, neither of which
Liveyon had.181
In response to this letter, Liveyon has suspended sales of the product
and will “ ‘focus its efforts’ on getting the nod from the FDA to conduct a
clinical trial and eventually apply for approval of the products.”182 The company argued that the FDA gave a “ ‘narrow interpretation’ of federal rules on
stem cells” by finding that their products required agency approval.183 They
continue to contend that they “appropriately marketed” their products.184
However, they believe “proving the efficacy of the product through FDA
clinical trials, is in the company’s best interest for the future.”185
IV. IMPLICATIONS ON PATIENT SAFETY
A. Balancing the Benefits and Risks of Stem Cell Therapies
These kinds of unregulated treatments have serious implications on patient’s health and safety.186 Claims of effectiveness and safety of a therapy
must be based on evidence to keep unsafe or ineffective therapies out of
routine use.187 Even in cases where therapeutic interventions are “pursued on
the basis of expert opinion and patient acceptance [the interventions] ultimately proved ineffective or harmful when studied in well-controlled trials
176. Id.
177. Warning Letter Liveyon Labs Inc., supra note 155.
178. Id.
179. Id.
180. Id.
181. Id.
182. McGinley, supra note 26.
183. Id.
184. Id.
185. Id.
186. Marks et al., supra note 9, at 1008–09.
187. Id. at 1008.
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comparing them with the standard of care.”188 Adverse effects are probably
more common in unregulated treatments than patients think because clinics
are not required to report adverse effects when administered outside of a
clinical trial.189 Potential safety concerns include administration site reactions, the ability of cells to move from the placement site and change into
inappropriate cell types or multiply, failure of cells to work as expected, and
the growth of tumors.190 Without clinical trials, the FDA cannot determine if
the clinical benefits outweigh these potential harms.191
B. Real Patient Stories
The impact on patients when treatments are offered without the determination of benefits and risks is illustrated by the patient stories in Bad
Batch.192 The podcast tells the story of Texas patients who received stem cell
treatments and later found themselves in the hospital with life-threatening
bacterial infections.193 Three patients that received treatment, with products
distributed by Liveyon from a Houston chiropractor, all wound up in intensive care during one weekend.194 One patient received injections in her shoulders and a couple days later was airlifted to a hospital because she was on the
verge of a heart attack and kidney failure.195 Even after two weeks in the
hospital and six more in rehab, she still has permanent damage from the
treatments.196 Another patient received treatment for severe neck pain and
was later admitted to the hospital with a 106 degree fever.197 The third patient
received treatment for pain in her back and was also rushed to the hospital.198
Both of these patients survived the infection; however, they are in more pain
than before the injections.199

188. Id.
189. Id.
190. Id.
191. Id. at 1009.
192. Beil, supra note 1.
193. Id.
194. Id.
195. Id.
196. Id.
197. Id.
198. Beil, supra note 1.
199. Id.

2020]Responses to Unproven Direct-to-Consumer Stem Cell Therapies 275

V. CONTINUING ISSUES WITH REGULATION
Despite the increased regulation and guidance to clarify these regulations, stakeholders still have concerns.200 Among these concerns are that
there still exists confusion when the HCT/P is considered under the same
surgery exception or minimally manipulated.201 Additionally, stakeholders
are worried about the FDA’s resources in executing these regulations.202 This
section discusses the stakeholder’s concerns and possible solutions the FDA
can take to correct the concerns.203
A. Same Surgical Procedure Exception
Stakeholders are concerned that the current definition of the same surgery exception fails to address certain uses of the stem cells.204 As the exception is written, it may not address nonhomologous use of the cells.205 So stem
cells that are isolated and re-implanted in the patient for purposes other than
their basic functions may still fall under the exception.206 The potential gap in
the regulations could create a pathway for businesses to circumvent regulations.207 Entities can use this exception on an unproven use of the stem cells
claiming that they do not fall under the higher tiers of regulations.208
The FDA’s purpose of this exception is that the removal and implantation of autologous cells or tissues without processing steps into the same
individual raises “no additional risks of contamination and communicable
disease transmission beyond that typically associated with surgery.”209 Additionally, the FDA has taken clear steps to increase their regulation of stem
cell therapies.210 The rationale for this regulation is to ensure patient safety
when the effects of the treatment may be unknown.211

200. PEW CHARITABLE TRS., supra note 12, at 16.
201. Id. at 16–17.
202. Id. at 19.
203. Id.
204. Id. at 16.
205. Id.
206. PEW CHARITABLE TRS., supra note 12, at 16. For example, bone marrow stem
cells may be re-implanted to treat a neurological condition. Id.
207. Id.
208. Id.
209. SAME SURGICAL PROCEDURE EXCEPTION, supra note 98, at 3.
210. FDA Warns About Stem Cell Therapies, supra note 60.
211. Id.
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Under these rationales, it would make sense for homologous use to be
required to apply in this exception.212 Without that clarification, entities can
use cells outside of their basic functions without any regulation for that treatment.213 This is precisely why the FDA has required clinical trials under the
FD&C Act or PHSA when cells or tissues are not intended for homologous
use.214 Further, this is the same argument used by clinics using adipose tissue
based therapies such as US Stem Cell Clinic, which the FDA has clearly
stated they do not agree with.215 Therefore, the FDA’s stance on if homologous use is required under the same surgical exception seems clear.216 However, additional clarity on the issue could ease the concerns of
stakeholders.217
B. Minimal Manipulation Definition
Even after the guidance given by the FDA, stakeholders still have difficulties determining what is considered minimal manipulation.218 This confusion comes from the “controversial” distinction between structural and
nonstructural tissue.219 While the guidance acknowledges that a tissue could
have both structural and nonstructural properties, it does not really explain
why it made that distinction.220 The guidance gives definitions for both kinds
of tissues and cells but does not truly offer how to determine when the HCT/

212. MINIMAL MANIPULATION AND HOMOLOGOUS USE, supra note 89, at 4 (explaining that non-homologous uses of cells increase safety concerns because they
make how the cells will function in the recipient unpredictable).
213. PEW CHARITABLE TRS., supra note 12, at 16.
214. MINIMAL MANIPULATION AND HOMOLOGOUS USE, supra note 89, at 4 (“This
criterion reflects the Agency’s conclusion that there would be increased safety
and effectiveness concerns for HCT/Ps that are intended for a non-homologous
use, because there is less basis on which to predict the product’s behavior,
whereas HCT/Ps for homologous use can reasonably be expected to function
appropriately.”).
215. Statement on Stem Cell Clinic Permanent Injunction, supra note 172.
216. See MINIMAL MANIPULATION

AND

HOMOLOGOUS USE, supra note 89, at 4.

217. PEW CHARITABLE TRS., supra note 12, at 19.
218. Id. at 17.
219. Id. at 16.
220. The FDA recognizes that structural tissues can contain cells and that some
manufacturers argue a single HCT/P has both a structural and nonstructural
tissue or cell functions. Despite this recognition, the FDA states that they are
considered in only one category under the regulations without explaining why.
MINIMAL MANIPULATION AND HOMOLOGOUS USE, supra note 89, at 7.
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Ps are in each category.221 Stakeholders have asked for more clarity from the
agency on how they will classify tissues and cells moving forward.222
This confusion among stakeholders potentially causes misperceptions
about whether the product is subject to the stringent premarket requirements,
and instead of seeking approval, manufacturers will just continue development and treatments on the assumption it is not required.223 This creates a
system of responding after the fact when treatments are already being marketed to patients.224 Offering additional guidance and clarity with less room
for interpretation on behalf of the manufacturer could increase safety and
efficacy of treatments.225 However, this could also stall innovations in the
field because manufacturers are not willing to go through the process.226
While giving the manufacturers clarity may have this disadvantage, it will
also give them an opportunity to be aware of and meet proper regulations
before the FDA takes action against them instead of attempting to come into
compliance after the fact.227
C. Roles of Other Agencies and State Actors
Stakeholders are concerned with the ability of the FDA to regulate all of
the clinics.228 The FDA has been using its resources to target higher risk
procedures, so lower risk manufacturers may believe they are exempt or that
the FDA tolerates noncompliance.229 While recent enforcement actions may
signal to providers that the FDA is serious, it would be more effective if a
wide population of providers are targeted.230 However, broad enforcement by
the agency requires additional funding, training, and staffing.231 Thus, there
is a need for congressional support for the full implementation of this frame221. The FDA states that the distinction is based on the differing safety and efficacy
concerns but does not offer further explanation in determining how the determination of structural versus nonstructural tissue or cells is made. Id. at 6.
222. PEW CHARITABLE TRS., supra note 12, at 17.
223. See MINIMAL MANIPULATION AND HOMOLOGOUS USE, supra note 89, at 6 (explaining how to apply the criteria to determine whether the restrictions apply).
224. Id. at 3–4 (explaining that if the minimally manipulated exception is met, along
with the other conditions, the product is not subject to premarket review).
225. PEW CHARITABLE TRS., supra note 12, at 17 (explaining that stakeholders request additional clarification in order to comply with these regulations).
226. Id. at 11 (explaining that higher regulatory burdens can pose obstacles to innovation and keep effective therapies out of the market).
227. See MINIMAL MANIPULATION AND HOMOLOGOUS USE, supra note 89, at 6; see
PEW CHARITABLE TRS., supra note 12, at 11.
228. PEW CHARITABLE TRS., supra note 12, at 19.
229. Id.
230. Id.
231. Id.
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work.232 But, there is also the potential for other agencies and actors to assist
in the regulation of these clinics.233
1. Federal Trade Commission
Both the FDA and FTC play roles in regulating health care products.234
The two agencies have previously agreed on their roles in this area.235 The
FDA regulates the advertising of prescription drug products and the FTC
regulates nonprescription drugs, devices, and cosmetics.236 However, in the
past it has not been clear who is in charge of regulating the advertising of
unproven stem cell treatments.237 But in 2018, the FTC brought charges
against a physician who advertised unapproved therapies, which potentially
set the stage for the agency to take over this area of regulation.238 The FTC
and the FDA could use a teamwork approach to target lower risk procedures
that do not have the stringent premarket and clinical trial requirements.239
The FTC brought charges against a physician and his companies because “[c]linics must have solid evidence to back up their claims before advertising that stem cell therapy can treat serious medical issues.”240 A
California physician claimed that his stem cell therapy was capable of treating a range of serious diseases such as Parkinson’s disease, multiple sclerosis, cerebral palsy, and chronic kidney disease.241 These claims were made on
the companies’ social media and websites.242 However, these claims were not
supported by scientific evidence.243 The charges brought by the FTC were
232. Id. at 20.
233. Id. at 21.
234. Liz Richardson, Federal Trade Commission Acts for First Time Against Stem
Cell Clinics, PEW CHARITABLE TRS. (Dec. 21, 2018), https://
www.pewtrusts.org/en/research-and-analysis/articles/2018/12/21/federal-tradecommission-acts-for-first-time-against-stem-cell-clinics.
235. Id.
236. Id.
237. Id.
238. Id.
239. Id.
240. FTC Stops Deceptive Health Claims by a Stem Cell Therapy Clinic, U.S. FED.
TRADE COMM’N (Oct. 18, 2018), https://www.ftc.gov/news-events/press-releases/2018/10/ftc-stops-deceptive-health-claims-stem-cell-therapy-clinic.
241. Id.
242. Colleen Tressler, FTC Takes Aim At Deceptive Stem Cell Therapy Claims, U.S.
FED. TRADE COMM’N: CONSUMER INFO. BLOG (Oct. 18, 2018), https://
www.consumer.ftc.gov/blog/2018/10/ftc-takes-aim-deceptive-stem-cell-therapy-claims.
243. FTC Stops Deceptive Health Claims by a Stem Cell Therapy Clinic, supra note
240.
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settled and the physician was prohibited from making health claims in the
future without scientific evidence supporting them.244 Additionally, the physician and the companies had to pay money to the FTC to be used to refund
consumers that were harmed by the deceptive advertising.245
This California settlement opened the door for the FTC to take a proactive role in overseeing the marketing of unproven treatments.246 Given the
number of clinics in the direct-to-consumer market, it is not feasible that
either agency could target every clinic.247 However, if the FTC followed this
precedent and took steps to regulate clinics it would send a clear message to
clinics that federal regulators are taking action to protect patients against unproven treatments.248 This could be particularly effective for regulating clinics that are not targeted by the FDA as high risk procedures. By ensuring that
the low-risk procedures are only marketed based on what they can actually
treat, patients will not be swayed by the promise of magic cures for all of
their ailments.249 However, even with both agencies taking actions against
clinics and manufacturers, it is still unlikely that their actions will reach all
the clinics.250 Thus, there may be some room for state actors to have a role in
regulating the clinics.
2. State Actors
The FDA and FTC are limited in how they regulate clinics because the
power to regulate the practice of medicine lies with the states.251 A physician
may use drugs and devices approved by the FDA in a way that is not supported by scientific evidence and go unnoticed by the FDA.252 Since each
state is regulated by its own board, the regulation of physicians in this respect
varies nationwide.253 For example, only seventeen boards reported investigat244. Id.
245. Id.
246. Richardson, supra note 234.
247. Id.
248. Id.
249. Murdoch et al., supra note 28, at 5 (discussing clinics’ use of hype language
and nondisclosure of inefficacy or risks of the treatment).
250. Richardson, supra note 234.
251. FED’N

OF STATE MED. BDS., REGENERATIVE AND STEM CELL THERAPY PRAC9 (2018), https://www.fsmb.org/siteassets/advocacy/policies/fsmb-stemcell-workgroup-report.pdf.
TICES

252. David Gorski, The Stem Cell Hard Sell: The Medical Board of California is
Forming A Task Force to Determine How to Regulate Physicians Offering
Stem Cell Therapies, SCI.-BASED MED. (Dec. 10, 2018), https://
sciencebasedmedicine.org/medical-board-of-california-is-forming-a-task-force/
.
253. See FED’N

OF

STATE MED. BDS., supra note 251, at 9.
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ing complaints against physicians conducting stem cell treatments.254 In addition to state medical boards, there is precedent for the involvement of state
attorneys general.255
In addition to federal regulation by the FTC, state attorneys general also
have a role in protecting patients form businesses selling unapproved treatments.256 For example, the New York Attorney General filed a lawsuit
against a clinic that deceived patients “into paying thousands of dollars for
unproven and potentially harmful stem cell procedures.”257 Similarly, in
North Dakota, the attorney general’s office investigated a clinic that was
making misleading claims.258 These actions by state officials prove how
states may supplement federal regulation of stem cell clinics.259 Due to the
large number of clinics in the United States, effective regulation requires a
broad approach by bodies “charged with protecting public health or protecting consumers from fraud.”260 The state attorneys general play an important
role in such regulation because they may target clinics in their state that are
marketing unproven treatments.261
In 2018, the Federation of State Medical Boards (FSMB) released recommendations for how state medical boards could get involved in monitoring the physicians who advertise stem cell treatments.262 The
recommendations focus on ensuring “patient safety, autonomy, and non-exploitation.”263 First, the FSMB noted the importance of data gathered from
the business’ website in the investigation of the complaints against the physicians.264 Additionally, the clinic’s social media and blogs could offer additional information in these investigations.265 Further, the FSMB suggests
boards could proactively monitor FDA warning letters, which are public information, in order to determine if an investigation against a physician
should be opened.266 Medical boards could also play a role in ensuring the
physicians are adequately trained to perform the treatments they are advertis254. Id.
255. Richardson, supra note 137.
256. Id.
257. Id.
258. Id.
259. Id.
260. Id.
261. See Richardson, supra note 137.
262. FED’N

OF

263. Id. at 10.
264. Id. at 4.
265. Id. at 10.
266. Id.

STATE MED. BDS., supra note 251, at 2.
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ing.267 This could be particularly important given the number of physicians
who offer stem cell treatments outside of their specialty.268 The FSMB recommendations also include guidance on how the state medical boards can
promote shared decision-making between the physician and the patient.269
While these recommendations offer guidance on best practices, it is not
clear how or if they will be implemented by individual state medical
boards.270 Some researchers have suggested this could be an important tool in
regulating physicians.271 Others, however, are unsure how effective state
boards would be in regulation.272 One critique is the lack of resources available to state medical boards.273 Another critique is that in the past medical
boards have been “notoriously unwilling to evaluate the science behind medical claims and crack down on other quackery.”274 Therefore, it is unlikely
the boards will go after these clinics that are so profitable.275 Additionally, it
could lead to innovation in states with less regulation on treatments, such as
Texas.276 Thus, while state medical boards could potentially fill in gaps in the
federal statutory structure, it does not come without its challenges. Even with
these challenges, the increase in patient safety suggests that such an approach
would be reasonable.277 Whatever the solution may be, it is clear that both
state and federal legislatures need to make this a priority in order to have
effective regulation.278

267. Id. at 11.
268. FED’N
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STATE MED. BDS., supra note 251, at 5.

269. Id. at 11.
270. PEW CHARITABLE TRS., supra note 12, at 24.
271. Wayne Fu et al., Characteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell Interventions, 324 JAMA 2463, 2464 (2019), https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC6593626/.
272. Gorski, supra note 252.
273. Id.
274. Id.
275. Id.
276. See Sipp, supra note 29, at 639–40 (explaining the process of “regulatory shopping” where clinics set up shop in areas with less regulation rather than complying with the strict regulations of an area).
277. Fu et al., supra note 271, at 5.
278. Gorski, supra note 252 (explaining the limited resources available to state medical boards); PEW CHARITABLE TRS., supra note 12, at 19 (discussing stakeholders’ concerns with the availability of resources for the FDA and FTC).
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VI. CONCLUSION
Regenerative medicine, and stem cell treatments in particular, have
caught the attention of many vulnerable patients who use these treatments as
their last hope.279 However, while physicians and patients are excited about
the potential of these treatments, regulators must be wary of the use of unproven treatments.280 The FDA has created a tiered regulatory structure that
heavily regulates treatments that are highly risky but has virtually no regulation for less risky treatments.281 Despite the FDA making statements that
stem cell treatments fall under their regulations,282 physicians continue to
market these therapies directly to consumers without the proper approval.283
These physicians and clinics interpret the tiers of regulation so that they fall
in the lowest tier, rather than the highest.284 But, without the use of clinical
trials, which apply to the higher risk treatments under the regulatory framework, there is no way to determine how safe and effective these procedures
are.285
As seen in the Bad Batch, these unproven procedures can have severe
negative implications for these vulnerable patients.286 These patients’ stories
are only a few examples of how clinics have been able to circumvent the
current regulatory framework.287 Liveyon was able to market its product to
patients, through free seminars and online, and distribute its product around
the country without regulators stepping in until patients were harmed.288
These patients’ stories exemplify why a proactive approach to regulation is
needed to ensure patient safety.
Within the current regulatory framework set out by the FDA, there are
still gaps in the regulation which may be filled in by other agencies and state
medical boards.289 One possibility is for the FTC to take a more proactive
role in monitoring and charging clinics and physicians who falsely advertise
the potential benefits of their treatments.290 The FTC opened the door to this
option in its settlement with a California physician who advertised that treat279. See Sipp, supra note 29, at 639.
280. FDA Warns About Stem Cell Therapies, supra note 60.
281. PEW CHARITABLE TRS., supra note 12, at 10.
282. FDA Warns About Stem Cell Therapies, supra note 60.
283. Murdoch et al., supra note 28, at 1.
284. Menon, supra note 32.
285. Marks et al., supra note 9, at 1008–09.
286. Beil, supra note 1.
287. Id. (“Providers figured out how to operate just inside the margins or simply
ignored the regulations.”).
288. Id.
289. PEW CHARITABLE TRS., supra note 12, at 21.
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ment could treat a long list of serious diseases without any scientific evidence to substantiate such a claim.291 Oversight from the FTC has the
potential to reach clinics whose procedures, while dangerous, are not the target of FDA enforcement.292
State medical boards can also play a role in the regulation of physicians
who are offering the stem cell treatments.293 Federal authority is necessarily
limited as they cannot regulate the practice of medicine, but the state medical
boards have this authority.294 The FSMB released recommendations for the
best practices of state medical boards in regulating these physicians, but it
has yet to be seen how they will be used by the states.295 The use of state
medical boards in this area of regulation could be important in ensuring that
the physicians are properly trained in the treatment they are offering and are
not working outside of their specialties, which is a common occurrence in the
direct-to-consumer stem cell treatments.296 Therefore, the use of the state actor and the FTC in partnership with the FDA could offer a more full regulatory structure that reaches all levels of the industry.297 For this to work,
however, these entities need the proper resources, such as funding, staffing,
and training.298 Thus, actors in the government on all levels need to prioritize
the protection of vulnerable patients from clinics offering unproven
treatments.
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